Form 4: DiaMedica Director and 10% Owner Jan Stahlberg Boosts Stake with $5.4 Million Share Purchase

DiaMedica Therapeutics Inc. saw a significant increase in insider ownership as Director and 10% owner Jan Stahlberg, through Trill AB, acquired over 1.5 million common shares for approximately $5.4 million.

Summary

• Jan Stahlberg, a Director and 10% Owner of DiaMedica Therapeutics Inc. (DMAC), acquired 1,542,857 common shares.
• The transaction occurred on July 23, 2025, at a price of $3.50 per share.
• The total value of the acquisition is approximately $5,399,999.50.
• Following this transaction, Jan Stahlberg, indirectly through Trill AB, beneficially owns 6,764,465 common shares.
• Jan Stahlberg is the sole owner and board member of Trill AB, which directly owns these shares.

Sentiment

Score: 9

Explanation: The significant purchase of shares by a director and 10% owner, totaling approximately $5.4 million, indicates very strong insider confidence and a positive outlook for the company's future. This type of transaction is generally viewed as a highly bullish signal.

Positives

• A Director and 10% owner, Jan Stahlberg, significantly increased his beneficial ownership in DiaMedica Therapeutics Inc., signaling strong confidence in the company's future.
• The acquisition of 1,542,857 common shares at $3.50 per share represents a substantial investment of approximately $5.4 million by an insider.
• The increased stake brings Jan Stahlberg's indirect beneficial ownership to 6,764,465 common shares, reinforcing alignment with shareholder interests.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance.

Industry Context

This filing indicates a significant insider investment in a biotechnology/pharmaceutical company, which can be a positive signal in an industry often characterized by high R&D costs and long development cycles, suggesting confidence in future product pipelines or market position.

Comparison to Industry Standards

• Insider purchases of this magnitude (over $5 million) by a director and significant owner are generally viewed very positively across all industries, as they demonstrate strong conviction in the company's valuation and prospects.
• Compared to typical insider transactions, this is a substantial investment, indicating more than just routine share accumulation.
• While specific comparable companies or projects are not mentioned in the filing, such a large insider buy often aligns with periods where management perceives the stock to be undervalued or expects significant positive developments.

Stakeholder Impact

• Shareholders: Positive impact due to increased insider confidence, potentially leading to increased investor confidence and share price appreciation.

Key Dates

Recommendation

The substantial purchase of shares by a Director and 10% owner, Jan Stahlberg, signals strong conviction in DiaMedica Therapeutics Inc.'s prospects. Insider buying of this magnitude (over $5 million) is a powerful indicator that those with the most intimate knowledge of the company believe its stock is undervalued or poised for significant positive developments. This action aligns management's interests more closely with shareholders and suggests a belief in future value creation, making it a compelling reason for investors to consider a "strong buy" position.

Keywords

DiaMedica Therapeutics, DMAC, Insider Trading, Form 4, Share Purchase, Beneficial Ownership, Jan Stahlberg, Trill AB, Director, 10% Owner, Biotechnology, Pharmaceuticals